Home > Resources > Whitepapers > Booming Biotech

Booming Biotech

The biotechnology industry has experienced accelerated growth in recent years. The major factor influencing this growth has been large pharmaceutical companies looking for their next blockbuster drug coupled with an aging population facing a long list of chronic diseases.

Spotlight

San Jose BioCenter

Accelerating the commercialization of science, the San Jose BioCenter provides a new generation of specialized facilities; capital equipment; laboratory services; and commercialization support for emerging science and technology companies. The BioCenter is a new, time and cost efficient model to commercialize innovation for emerging science and technology companies. Since inception, the life science and clean technology companies of the BioCenter have raised more than $800M in capital and have created more than 600 direct jobs.

OTHER WHITEPAPERS

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Read More

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More

Biotech Talent Management

whitePaper | February 2, 2022

While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.

Read More

2022 Global Life Sciences Outlook

whitePaper | January 7, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the sector is healthy

Read More

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable of producing high concentrations of peptides.

Read More

BIOTECHNOLOGY UPDATE

whitePaper | April 24, 2022

The Global Forum on Biotechnology, established in 2010, is one of 15 Global Fora created by OECD Committees. Global Fora are not official OECD bodiesbut are best described as broad.

Read More

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Read More

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More

Biotech Talent Management

whitePaper | February 2, 2022

While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.

Read More

2022 Global Life Sciences Outlook

whitePaper | January 7, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the sector is healthy

Read More

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable
of producing high concentrations of peptides.

Read More

BIOTECHNOLOGY UPDATE

whitePaper | April 24, 2022

The Global Forum on Biotechnology, established in 2010, is one of 15 Global Fora created by OECD Committees. Global Fora are not official OECD bodies but are best described as broad.

Read More

More Whitepapers

Spotlight

San Jose BioCenter

Accelerating the commercialization of science, the San Jose BioCenter provides a new generation of specialized facilities; capital equipment; laboratory services; and commercialization support for emerging science and technology companies. The BioCenter is a new, time and cost efficient model to commercialize innovation for emerging science and technology companies. Since inception, the life science and clean technology companies of the BioCenter have raised more than $800M in capital and have created more than 600 direct jobs.

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference